First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations

Add-On To Schizophrenia, Bipolar Depression Indications

With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.

Depiction of fear, loneliness, depression, abuse, addiction
Lumateperone met the primary and secondary endpoints in MDD • Source: Shutterstock

Intra-Cellular Therapies, Inc. reported positive results on 16 April from the first Phase III clinical trial of Caplyta (lumateperone) in major depressive disorder (MDD) that exceeded expectations for the study and increased speculation that the drug would add to the drug’s blockbuster potential. Assuming a second Phase III trial in MDD is positive when it reads out late in the second quarter of 2024, the company plans to file for supplemental approval in the third indication later this year.

Key Takeaways
  • Intra-Cellular Therapies reported positive results from the first Phase III study of Caplyta (lumateperone) as an adjunct to antidepressant therapies in major depressive disorder (MDD).

The US Food and Drug Administration approved the atypical antipsychotic Caplyta for adults with schizophrenia in December 2019 and as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: Organon To Pull Plug On OG-6219 Program After Phase II Endometriosis Trial Failure

 

Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By 

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

More from R&D

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By 

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.